Abstract:
:The movement toward precision medicine with targeted therapeutics for cancer treatment has been hindered by both innate and acquired resistance. Understanding the molecular wiring and plasticity of oncogenic signaling networks is essential to the development of therapeutic strategies to avoid or overcome resistance. The mechanistic target of rapamycin (mTOR) complex 1 (mTORC1) represents a highly integrated signaling node that is dysregulated in the majority of human cancers. Several studies have revealed that sustained mTORC1 inhibition is essential to avoid resistance to targeted therapeutics against the driving oncogenic pathway in a given cancer. Here we discuss the role of mTORC1 in dictating the response of tumors to targeted therapeutics and review recent examples from lung cancer, breast cancer, and melanoma.
journal_name
Trends Cancerjournal_title
Trends in cancerauthors
Ilagan E,Manning BDdoi
10.1016/j.trecan.2016.03.008subject
Has Abstractpub_date
2016-05-01 00:00:00pages
241-251issue
5eissn
2405-8033issn
2405-8025journal_volume
2pub_type
杂志文章相关文献
Trends in Cancer文献大全abstract::The Abelson (ABL) tyrosine kinases were identified as drivers of leukemia in mice and humans. Emerging data has shown a role for the ABL family kinases, ABL1 and ABL2, in the progression of several solid tumors. This review will focus on recent reports of the involvement of the ABL kinases in tumor progression using m...
journal_title:Trends in cancer
pub_type: 杂志文章
doi:10.1016/j.trecan.2015.07.004
更新日期:2015-10-01 00:00:00
abstract::Dicer-deficient cancers have poor prognoses, which is linked to the degradation of tumour-suppressing miRNA precursors by the Translin-Trax (Tn-Tx) ribonuclease. Inhibition of Tn-Tx potentially offers a new therapeutic intervention point. However, Tn-Tx functions in an array of biological processes, and here we consid...
journal_title:Trends in cancer
pub_type: 杂志文章
doi:10.1016/j.trecan.2020.02.014
更新日期:2020-06-01 00:00:00
abstract::TP53 is the most frequently mutated gene in breast cancer, but its role in survival is confounded by different studies concluding that TP53 mutations are associated with negative, neutral, or positive outcomes. Closer examination showed that many studies were limited by factors such as imprecise methods to detect TP53...
journal_title:Trends in cancer
pub_type: 杂志文章,评审
doi:10.1016/j.trecan.2020.01.007
更新日期:2020-02-01 00:00:00
abstract::The survival rate of reproductive-age patients with cancer is increasing, reflecting the advent of better and more efficient therapies. Cancer survivors seek the resumption of a normal and healthy life, which often includes starting a family. Unfortunately, many cancer treatments increase the risk of premature ovarian...
journal_title:Trends in cancer
pub_type: 杂志文章,评审
doi:10.1016/j.trecan.2016.03.006
更新日期:2016-05-01 00:00:00
abstract::Dysregulation of the PI3K/PTEN pathway is a frequent event in cancer, and PIK3CA and PTEN are the most commonly mutated genes after TP53. PIK3R1 is the predominant regulatory isoform of PI3K. PIK3R2 is an ubiquitous isoform that has been so far overlooked, but data from The Cancer Genome Atlas shows that increased exp...
journal_title:Trends in cancer
pub_type: 杂志文章,评审
doi:10.1016/j.trecan.2019.02.009
更新日期:2019-04-01 00:00:00
abstract::The rapidly evolving field of cancer immunotherapy recently saw the approval of several new therapeutic antibodies. Several cell therapies, for example, chimeric antigen receptor-expressing T cells (CAR-T), are currently in clinical trials for a variety of cancers and other diseases. However, approaches to monitor cha...
journal_title:Trends in cancer
pub_type: 杂志文章,评审
doi:10.1016/j.trecan.2018.03.009
更新日期:2018-05-01 00:00:00
abstract::Given the implication of aberrant RAS-extracellular signal-regulated kinase (ERK) signaling in the development of a large number of tumor types, this route is under intense scrutiny to identify new anticancer drugs. Most avenues in that direction have been primarily focused on the inhibition of the catalytic activity ...
journal_title:Trends in cancer
pub_type: 杂志文章,评审
doi:10.1016/j.trecan.2018.07.002
更新日期:2018-09-01 00:00:00
abstract::Curative therapy for cancer patients with advanced-stage disease remains elusive. While rare outlier responses to anticancer therapies exist, barriers limit our understanding of the molecular and genetic basis of such profound, life-altering responses. Here, we describe how phenotype-to-genotype studies are elucidatin...
journal_title:Trends in cancer
pub_type: 杂志文章,评审
doi:10.1016/j.trecan.2017.11.004
更新日期:2018-01-01 00:00:00
abstract::The tumor microenvironment has an essential role in defining tumor malignancy, since it can either promote or prevent tumor initiation and subsequent progression and metastatic dissemination. Recent studies demonstrate that highly aggressive cancer cells display a high degree of metabolic plasticity paralleled by the ...
journal_title:Trends in cancer
pub_type: 杂志文章,评审
doi:10.1016/j.trecan.2016.11.001
更新日期:2016-12-01 00:00:00
abstract::Innate lymphoid cells (ILCs) fulfill important protective and reparative functions, and have thus been implicated in the maintenance of tissue homeostasis. Dysregulation of their activation is associated with several autoimmune and inflammatory diseases. The current literature on the role of ILCs in cancer is limited ...
journal_title:Trends in cancer
pub_type: 杂志文章,评审
doi:10.1016/j.trecan.2017.03.008
更新日期:2017-05-01 00:00:00
abstract::Alterations in protein ubiquitylation and hypoxia are commonly associated with cancer. Ubiquitylation is carried out by three sequentially acting ubiquitylating enzymes and can be opposed by deubiquitinases (DUBs), which have emerged as promising drug targets. Apart from protein localization and activity, ubiquitylati...
journal_title:Trends in cancer
pub_type: 杂志文章,评审
doi:10.1016/j.trecan.2019.08.005
更新日期:2019-10-01 00:00:00
abstract::The 'mild' cold stress caused by standard sub-thermoneutral housing temperatures used for laboratory mice in research institutes is sufficient to significantly bias conclusions drawn from murine models of several human diseases. We review the data leading to this conclusion, discuss the implications for research and s...
journal_title:Trends in cancer
pub_type: 杂志文章,评审
doi:10.1016/j.trecan.2016.03.005
更新日期:2016-04-01 00:00:00
abstract::Traditionally, the efficacy of novel cancer therapies has been confirmed in patients failing regular treatment before being tested in early disease. Improved understanding of the mechanisms guiding therapeutic efficacy may challenge this dogma, suggesting novel therapies to move into early evaluation based on biologic...
journal_title:Trends in cancer
pub_type: 杂志文章
doi:10.1016/j.trecan.2020.11.010
更新日期:2020-12-22 00:00:00
abstract::Lysophosphatidate (LPA) is emerging as a potent mediator of cancer progression in the tumor microenvironment. Strategies for targeting LPA signaling have recently entered clinical trials for fibrosis. These therapies have potential to improve the efficacies of existing chemotherapies and radiotherapy by attenuating ch...
journal_title:Trends in cancer
pub_type: 杂志文章,评审
doi:10.1016/j.trecan.2017.09.004
更新日期:2017-11-01 00:00:00
abstract::Even though we have known for over 250 years that cancers spread to regional lymph nodes (LNs) and distant organs, the fundamental question of which anatomical routes are taken by tumor cells has remained a mystery. Two recently published papers in Science, by Pereira et al. and Brown et al., directly address this imp...
journal_title:Trends in cancer
pub_type: 评论,杂志文章
doi:10.1016/j.trecan.2018.05.007
更新日期:2018-08-01 00:00:00
abstract::The identification of STING as a key cytoplasmic innate recognition molecule for DNA viruses whose function is lost in a variety of cancers has coincided with the approval of IMLYGIC for metastatic melanoma. This represents the first replication competent viral therapy approved for the treatment of any cancer in the U...
journal_title:Trends in cancer
pub_type: 杂志文章
doi:10.1016/j.trecan.2016.01.002
更新日期:2016-02-01 00:00:00
abstract::Dynamic changes in the colorectal cancer (CRC) signalome and tumor genetic heterogeneity underlie acquired drug resistance. Improving treatment-related decisions is facilitated by an emerging consensus in the classification of tumor subtypes as well as by real-time monitoring of predictive biomarkers in circulating tu...
journal_title:Trends in cancer
pub_type: 杂志文章,评审
doi:10.1016/j.trecan.2017.01.003
更新日期:2017-03-01 00:00:00
abstract::In this commentary, we review the timeline of clinical trials and regulatory actions of approved immune checkpoint inhibitors for small cell lung cancer, discuss challenges faced by regulatory agencies, and highlight paradoxical lessons that emerge. Accelerated approvals may fail to expedite drugs to market in this se...
journal_title:Trends in cancer
pub_type: 杂志文章
doi:10.1016/j.trecan.2020.05.014
更新日期:2020-09-01 00:00:00
abstract::The extremely high cancer incidence associated with patients suffering from a rare human genetic disease, Fanconi anemia (FA), demonstrates the importance of FA genes. Over the course of human tumor development, FA genes perform critical tumor-suppression roles. In doing so, FA provides researchers with a unique genet...
journal_title:Trends in cancer
pub_type: 杂志文章,评审
doi:10.1016/j.trecan.2017.10.005
更新日期:2017-12-01 00:00:00
abstract::Patients with advanced prostate cancer (PCa) frequently develop skeletal metastases that are associated with fractures, disability, and increased mortality. Within the bone metastatic niche, mutual interactions between tumor cells and osteoblasts have been proposed as major contributors of osteotropism by PCa. Here, w...
journal_title:Trends in cancer
pub_type: 杂志文章,评审
doi:10.1016/j.trecan.2020.09.006
更新日期:2021-02-01 00:00:00
abstract::Prostate cancer affects one in every nine men in the USA and is the second leading cause of cancer-related death. The treatment landscape of advanced prostate cancer is changing rapidly. Multiple agents including abiraterone, enzalutamide, apalutamide, darolutamide, docetaxel, cabazitaxel, radium-223, and sipuleucel-T...
journal_title:Trends in cancer
pub_type: 杂志文章,评审
doi:10.1016/j.trecan.2020.04.010
更新日期:2020-08-01 00:00:00
abstract::Immuno-oncology has gained momentum thanks to the success of strategies aimed at enhancing immune-mediated antitumor response. The field of immunotherapeutic transport oncophysics investigates the physical processes that drive cancer immunotherapies. This review discusses three main aspects that determine the outcome ...
journal_title:Trends in cancer
pub_type: 杂志文章,评审
doi:10.1016/j.trecan.2019.11.008
更新日期:2020-01-01 00:00:00
abstract::The pace of genomic and immunological breakthroughs in oncology is accelerating, making it likely that large randomized trials will increasingly become outdated before their completion. Traditional clinical research/practice paradigms must adapt to the reality unveiled by genomics, especially the need for customized d...
journal_title:Trends in cancer
pub_type: 杂志文章,评审
doi:10.1016/j.trecan.2017.12.004
更新日期:2018-02-01 00:00:00
abstract::Cancer of unknown primary (CUP) is a rare malignancy that presents with metastatic disease and no identifiable site of origin. Most patients have unfavorable features and attempts to treat based on tissue-of-origin identification have not yielded a survival advantage compared with empiric chemotherapy. Next-generation...
journal_title:Trends in cancer
pub_type: 杂志文章,评审
doi:10.1016/j.trecan.2020.11.002
更新日期:2021-01-27 00:00:00
abstract::Tumor heterogeneity is a large conundrum in cancer medicine, making most therapeutic interventions palliative rather than curative. Here we discuss the implications of how molecularly targeted therapies in solid malignancies that promote limited cancer cell death may in fact make tumors more heterogeneous, increase ag...
journal_title:Trends in cancer
pub_type: 杂志文章
doi:10.1016/j.trecan.2020.01.010
更新日期:2020-04-01 00:00:00
abstract::Lactate dehydrogenase (LDH) accounts for the fermentative component of aerobic glycolysis, a near ubiquitous metabolic alteration in cancer. Recently, Oshima et al. developed a bioavailable LDH inhibitor that decreases tumor growth in mice and functions synergistically with mitochondrial respiration inhibitors. These ...
journal_title:Trends in cancer
pub_type: 杂志文章
doi:10.1016/j.trecan.2020.02.012
更新日期:2020-05-01 00:00:00
abstract::GLI-similar 1-3 (GLIS1-3), a subfamily of Krüppel-like zinc finger transcription factors, function as key regulators of several biological processes important to oncogenesis, including control of cell proliferation, differentiation, self-renewal, and epithelial-mesenchymal transition. This review provides a short over...
journal_title:Trends in cancer
pub_type: 杂志文章,评审
doi:10.1016/j.trecan.2019.07.005
更新日期:2019-09-01 00:00:00
abstract::Regular exercise reduces the risk of cancer. One potential mechanism for this efficacy is improved antitumor immunity. This is an important issue because evading immune destruction is a hallmark of cancer and immunotherapy is reshaping cancer treatment. Here we review recent developments reported by Wennerberg et al.,...
journal_title:Trends in cancer
pub_type: 杂志文章
doi:10.1016/j.trecan.2020.12.003
更新日期:2021-02-01 00:00:00
abstract::Cancer-associated fibroblasts (CAFs) are one of the most significant components in the tumour microenvironment (TME), where they can perform several protumourigenic functions. Several studies have recently reported that CAFs are more heterogenous and plastic than was previously thought. As such, there has been a shift...
journal_title:Trends in cancer
pub_type: 杂志文章,评审
doi:10.1016/j.trecan.2019.09.010
更新日期:2019-11-01 00:00:00
abstract::The repurposing of existing non-cancer drugs is a potential source of new treatment options for cancer patients with high unmet medical needs. While scientific research is progressing rapidly in the field of drug repurposing, the implementation of drug repurposing still faces important financial and regulatory hurdles...
journal_title:Trends in cancer
pub_type: 杂志文章
doi:10.1016/j.trecan.2017.06.007
更新日期:2017-08-01 00:00:00